Sujet non disponible
Généralités
Select a topic to solve related cases or follow a course topic
-
Topic 1NEW --- Handling AEs of targeted therapies for metastatic UCa
-
Topic 2Finding the right ADT for the right patient
-
Topic 3Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 4NEW---High-risk non-metastatic prostate cancer
-
Topic 5NEW --- Management of non-metastatic castration-resistant prostate cancer
-
Topic 6NEW --- Treatment selection in mCRPC patients harbouring HRR gene mutations
-
Topic 7High-risk non-metastatic prostate cancer
-
Topic 8Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 9Finding the right ADT for the right patient
-
Topic 10NEW --- Targeted therapies for metastatic UCa in special populations
-
Topic 11NEW --- Molecular diagnostics in the era of targeted therapies for mUCa
-
Topic 12Adjuvant treatment approaches for MIBC
-
Topic 13Histological subtypes of (N)MIBC: managed differently compared to pure UCa?
-
Topic 14First-line therapy of synchronous and metachronous metastatic UCa
-
Topic 15New hope for patients progressing after prior treatment for mUCa
-
Topic 16Initial treatment of MIBC
-
Topic 17Follow-up surveillance regimes to consider for (very) high-risk NMIBC and MIBC
-
Topic 18Follow-up surveillance regimes for low-/intermediate-risk NMIBC
-
Topic 19Low- and intermediate-risk NMIBC: surveillance or intravesical therapy?
-
Topic 20Systemic therapy for HER2-positive early breast cancer
-
Topic 21First-line systemic therapy in metastatic renal cell carcinoma
-
Topic 22Systemic therapy for mRCC: second line and beyond
-
Topic 23Adjuvant systemic treatment of luminal A/B early breast cancer in premenopausal women
-
Topic 24Adjuvant systemic treatment of luminal A/B early breast cancer in postmenopausal women
-
Topic 25Management of small renal masses
-
Topic 26Systemic therapy for early stage TNBC
-
Topic 27Local therapy for mRCC
-
Topic 28Radiotherapy for early breast cancer
-
Topic 29Management of HER2+ MBC
-
Topic 30Brain metastases in patients with HER2+ breast cancer
-
Topic 31CDK4/6 inhibitors for everyone? Treatment strategies in HR+ HER2- advanced breast cancer
-
Topic 32Theragnostic testing – choosing the right therapy in mTNBC
-
Topic 33Challenges in high-risk NMIBC